Precision BioLogic originally developed CRYOcheck Chromogenic Factor VIII in response to a growing demand for chromogenic assays 1. Launched in 2020, it was the first commercially available, ...

HALIFAX, NS, Sept. 10, 2025 /CNW/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the expanded utility of its CRYOcheck Chromogenic Factor VIII ...

Proven CRYOcheck™ Chromogenic Factor VIII assay now offers expanded utility in anticipation of emerging treatments HALIFAX, NS, Sept. 10, 2025 /PRNewswire/ -- Precision BioLogic Inc., a leading ...

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat ® KMT2A + MRD Assay and Software ...

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, announced the addition of the LeukoStrat KMT2A + MRD Assay and Software to its industry-leading oncology ...